PeptiDream Inc.

Equities

4587

JP3836750004

Biotechnology & Medical Research

Delayed Japan Exchange Other stock markets 10:30:00 2024-05-20 pm EDT			5-day change	1st Jan Change
1,856 ^JPY	-3.13%		-8.37%	+24.82%

May. 07	Jefferies Adjusts PeptiDream’s Price Target to 1,900 Yen From 1,400 Yen, Keeps at Hold	MT
Apr. 30	Peptidream Announces Expansion of Peptide Discovery Collaboration with Novartis	CI

PeptiDream Inc. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2021

February 10, 2021 at 01:30 am EST

PeptiDream Inc. provided Non-consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2021. For the period, the company expects net sales to be of JPY 11,000 Million or more. Operating income expected to be of JPY 5,000 Million or more. Net income expected to be of JPY 3,600 Million or more.

Latest news about PeptiDream Inc.

Jefferies Adjusts PeptiDream’s Price Target to 1,900 Yen From 1,400 Yen, Keeps at Hold	May. 07	MT
Peptidream Announces Expansion of Peptide Discovery Collaboration with Novartis	Apr. 30	CI
PeptiDream Inc. Announces Expansion of Peptide Discovery Collaboration with Novartis Pharma AG	Apr. 30	CI
Certain Preferred Stock of RayzeBio, Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024.	Mar. 12	CI
Certain Stock Options of RayzeBio, Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024.	Mar. 12	CI
Certain Common Stock of RayzeBio, Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024.	Mar. 12	CI
PeptiDream to Partake in Bristol Myers' Tender Offer for All RayzeBio Shares	Feb. 15	MT
PeptiDream Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2024	Feb. 14	CI
PeptiDream Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 14	CI
Jefferies Adjusts PeptiDream's Price Target to 1,400 Yen From 1,300 Yen, Keeps at Hold	Jan. 24	MT
Linqmed Inc. announced that it has received ¥680 million in funding from a group of investors	Dec. 21	CI
PeptiDream Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	Nov. 09	CI
Jefferies Downgrades PeptiDream to Hold From Buy, Adjusts Price Target to 1,300 Yen From 1,600 Yen	23-10-27	MT
PeptiDream and Bristol-Myers Squibb to Explore Alternatives as PDL1 Program Faces Setback	23-10-27	MT
Peptidream Announces Update on PDL1 Program Partnered with Bristol-Myers Squibb Company	23-10-26	CI
Jefferies Upgrades PeptiDream to Buy From Hold, Adjusts Price Target to 1,600 Yen From 1,900 Yen	23-10-18	MT
PeptiDream Inc. Announces Collaboration and License Agreement with Genentech for the Discovery and Development of Novel Peptide- Radioisotope Drug Conjugates	23-09-19	CI
RayzeBio, Inc. has completed an IPO in the amount of $310.9968 million.	23-09-14	CI
PeptiDream Unit Pays 4 Billion Yen Contingent Consideration for AMYViD Indication Change; Shares Down 3%	23-09-10	MT
PeptiDream Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023	23-08-09	CI
PeptiDream Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-09	CI
Astellas Pharma Inc. and PeptiDream Inc. Enter into Research Collaboration and License Agreement to Discover Novel Targeted Protein Degraders	23-07-25	CI
Jefferies Downgrades PeptiDream to Hold From Buy, Adjusts Price Target to 1,900 Yen From 2,200 Yen	23-07-18	MT
PeptiDream Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
PeptiDream Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2023	23-05-11	CI

Chart PeptiDream Inc.

Duration

Period

More charts

Company Profile

PeptiDream Inc. is a Japan-based bio-venture company started by the University of Tokyo and principally engaged in the discovery and development of non-standard peptide therapeutics. The Company operates the Peptide Discovery Platform System (PDPS), a drug development platform system and conducts research and development (R&D) on new drug candidates based on the joint R&D with pharmaceutical companies in Japan and overseas. The Company is involved in the business centered on drug development based on special peptides. The Company's businesses include drug discovery joint R&D, PDPS technology loan (PDPS technology license) and expansion of its own pipeline through strategic alliance (strategic alliance or in-house drug discovery).

Sector

Biotechnology & Medical Research

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for PeptiDream Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1,916 JPY

Average target price

2,750 JPY

Spread / Average Target

+43.57%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PEPTIDREAM INC.	+24.82%	1.54B
VERTEX PHARMACEUTICALS INCORPORATED	+9.58%	115B
REGENERON PHARMACEUTICALS, INC.	+12.41%	106B
ARGENX SE	-2.59%	21.96B
BIONTECH SE	-12.38%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-3.35%	18.08B
WUXI APPTEC CO., LTD.	-38.57%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.51%	14.32B
SAREPTA THERAPEUTICS, INC.	+35.67%	12.42B

Bio Therapeutic Drugs